【私募调研记录】永禧投资调研维力医疗

Group 1 - The core viewpoint of the article highlights that Yongxi Investment has conducted research on a listed company, Weili Medical, focusing on its strategies to expand overseas production in response to domestic medical consumables procurement and geopolitical risks [1] - Weili Medical is actively building a factory in Mexico starting in 2024, having completed land acquisition and project planning, while also preparing a second overseas production base in Indonesia to mitigate high tariffs imposed by the U.S. [1] - The company expects that by 2024, overseas business will account for approximately 54% of its total revenue, with North America contributing 34%, Europe 27%, Asia 15%, and South America 8% [1] Group 2 - Weili Medical has seen a significant increase in the gross profit margin of its overseas business, rising from 27% in 2021 to 35% in 2024, an increase of 8 percentage points [1] - The company is diversifying its export products, with a growing proportion of high-margin products being exported, which contributes to the overall improvement in gross profit margins [1]